A novel complement C3 inhibitor CP40-KK protects against experimental pulmonary arterial hypertension via an inflammasome NLRP3 associated pathway.
Journal Information
Full Title: J Transl Med
Abbreviation: J Transl Med
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declarations Ethics approval and consent to participateThis study was performed in compliance with the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85–23, revised 1996), and all animal procedures and protocols were approved by the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology (Wuhan, China). Approval Code: No: TJH-202306044. Consent for publicationNot applicable. Competing interestsThe remaining authors have nothing to disclose. Competing interests The remaining authors have nothing to disclose."
"Funding This work was supported by the National Natural Science Foundation of China (No. 81873523; No. 82070490) to HZ."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025